Cara Therapeutics (CARA): Raising PT After Management Meetings - Piper Jaffray
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Cara Therapeutics (NASDAQ: CARA) and raised his price target to $21 after hosting management for investor meetings.
The analyst sees the potential for significant upside driven by clinical efficacy data from the company’s three lead programs - IV ‘845 in acute pain, IV ‘845 in uremic pruritus, oral ‘845 in OA – within the next 3-6 months. The belief is based on both the time with management and the analyst's ongoing due diligence.
The analyst stated "Cara not only has a differentiated, broadly applicable pipeline in a product for pain and itch, but has thoughtfully designed current studies to maximize signal in what can be noisy indications. After what has been mostly an execution year in 2016, we expect these design choices to pay off with positive top-line results and interim updates in 1H17. In advance of potentially transformational clinical progress for Cara from three near-term shots on the KOR goal".
The new $21 PT jumps from $16 on rolling forward the discount period to YE17 from YE16 for all programs without changing the 25% discount rate.
Shares of Cara Therapeutics closed at $9.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
- JPMorgan Raises Rating on CBOE Holdings (CBOE) to 'Overweight'; Analyst Thinks Bats Technology Will Drive Greater Trading Activity
- Shopify (SHOP): CFO Meetings Indicate Strong Growth Ahead - Wedbush
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Management Comments
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!